- Report
- February 2024
- 120 Pages
Global
From €4562EUR$4,750USD£3,928GBP
- Report
- June 2020
- 753 Pages
Global
From €3170EUR$3,300USD£2,729GBP
- Report
- March 2018
- 330 Pages
Global
From €2881EUR$3,000USD£2,481GBP
- Report
- September 2021
- 40 Pages
China
From €2497EUR$2,600USD£2,150GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£827GBP
Zometa is a brand of oncology drug used to treat bone metastases and other bone diseases. It is a bisphosphonate, a type of drug that helps to reduce the risk of fractures and other bone complications in cancer patients. Zometa is administered intravenously and works by inhibiting the activity of osteoclasts, cells that break down bone tissue. It is used to treat a variety of cancers, including breast, prostate, and lung cancer.
Zometa is a widely used drug in the oncology market, and is often prescribed in combination with other treatments. It is generally well-tolerated, with few side effects. Common side effects include nausea, vomiting, and constipation.
The oncology market is highly competitive, with many companies offering similar products. Some of the major players in the Zometa market include Novartis, Amgen, and Merck. Other companies, such as Teva Pharmaceuticals and Pfizer, also offer generic versions of the drug. Show Less Read more